regulatory
confidence high
sentiment positive
materiality 0.75
FDA approves Arcutis' ZORYVE foam for seborrheic dermatitis in ages 9+
Arcutis Biotherapeutics, Inc.
- ZORYVE (roflumilast) topical foam 0.3% approved by FDA for seborrheic dermatitis.
- Indicated for individuals 9 years of age and older.
- Prior FDA approval exists for ZORYVE cream 0.3% for plaque psoriasis (ages 6+).
- Approval expands Arcutis' commercial product portfolio into a new dermatology indication.